Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 10/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.39 |
| ▸ | TEK | Q02763 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5688981 | 0.82 | CYP17A1 (0.45) | CYP17A1CYP3A4CNR1CNR2SCN9A | |
| SCHEMBL5688374 | 0.82 | CYP17A1 (0.63) | CYP17A1CYP3A4 | |
| SCHEMBL29478298 | 0.81 | CYP17A1 (0.66) | CYP17A1CYP3A4 | |
| SCHEMBL5688564 | 0.81 | CYP17A1 (0.66) | CYP17A1CYP3A4 | |
| SCHEMBL7563594 | 0.81 | CYP17A1 (0.66) | CYP17A1CYP3A4 | |
| SCHEMBL5689203 | 0.81 | CYP17A1 (0.45) | CYP17A1CYP3A4CNR2SCN9A | |
| SCHEMBL5688705 | 0.81 | CYP17A1 (0.44) | CYP17A1CYP3A4CNR1CNR2SCN9A | |
| SCHEMBL5689065 | 0.80 | CYP17A1 (0.48) | CYP17A1CYP3A4CNR1 | |
| SCHEMBL5688359 | 0.79 | CYP17A1 (0.43) | CYP17A1CYP3A4 | |
| SCHEMBL5689078 | 0.77 | CYP17A1 (0.56) | CYP17A1CYP3A4CNR1CNR2EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227086-B1 | 1-SUBSTITUTED PHENYL-1-(1H-IMIDAZOL-4-YL) ALCOHOLS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-03-29 | — | — | EP | claimed |
| US-6518257-B1 | 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-11 | — | — | US | claimed |
| EP-1227086-A1 | 1-SUBSTITUTED PHENYL-1-(1H-IMIDAZOL-4-YL) ALCOHOLS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-07-31 | — | — | EP | claimed |
| EP-3365330-B1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIV OF TECHNOLOGY (ZA) | 2023-06-07 | — | — | EP | disclosed |
| EP-3365819-B1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIV OF TECHNOLOGY (ZA) | 2023-06-07 | — | — | EP | disclosed |
| US-11548860-B2 | Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of CYP17A1 and CYP19A1 | MANGOSUTHU UNIVERSITY OF TECHNOLOGY (ZA) | 2023-01-10 | — | — | US | disclosed |
| US-20200247764-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIVERSITY TECHNOLOGY (ZA) | 2020-08-06 | — | — | US | disclosed |
| US-20200247794-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIVERSITY TECHNOLOGY (ZA) | 2020-08-06 | — | — | US | disclosed |
| EP-3365330-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | Mangosuthu University Of Technology (ZA) | 2018-08-29 | — | — | EP | disclosed |
| EP-3365819-A2 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | Mangosuthu University Of Technology (ZA) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017070719-A2 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIVERSITY OF TECHNOLOGY (ZA) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070718-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIVERSITY OF TECHNOLOGY (ZA) | 2017-04-27 | — | — | WO | disclosed |
| EP-1227086-B1 | 1-SUBSTITUTED PHENYL-1-(1H-IMIDAZOL-4-YL) ALCOHOLS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-6518257-B1 | 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-1227086-A1 | 1-SUBSTITUTED PHENYL-1-(1H-IMIDAZOL-4-YL) ALCOHOLS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247794-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | CYP19A1, CYP26A1, CYP21A2 | CYP17A1 5/4885CYP3A4 48/4885CNR1 553/4885 |
| US-20200247764-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | CYP19A1, CYP26A1, CYP21A2 | CYP17A1 10/4885CYP3A4 18/4885CNR1 292/4885 |
| US-11548860-B2 | Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of CYP17A1 and CYP19A1 | CYP19A1, CYP26A1, CYP21A2 | CYP17A1 10/4885CYP3A4 18/4885CNR1 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.